Junshi Biosciences: New drugs JS203 and JS207 are expected to enter Phase III clinical trials within 2026.

Junshi Biosciences stated at its 2026 interim results briefing held on September 14 that the Phase III clinical study of its new drug JS203 is expected to be initiated within 2026; JS207 is already in Phase II clinical studies, with combination explorations underway with different agents such as chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types, and a Phase III clinical study is planned to be initiated within 2026.